Compare JFIN & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFIN | EOLS |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.9M | 304.0M |
| IPO Year | 2018 | 2018 |
| Metric | JFIN | EOLS |
|---|---|---|
| Price | $6.25 | $5.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.40 |
| AVG Volume (30 Days) | 57.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | ★ 13.03% | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | N/A | $14.41 |
| Revenue Next Year | N/A | $16.96 |
| P/E Ratio | $1.35 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $5.73 | $4.09 |
| 52 Week High | $18.70 | $13.81 |
| Indicator | JFIN | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 68.56 |
| Support Level | $5.81 | $4.74 |
| Resistance Level | $6.70 | $7.29 |
| Average True Range (ATR) | 0.30 | 0.28 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 43.75 | 75.58 |
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.